


WHAT IS XLH?

PAEDIATRIC features¹

- Delayed and disproportionate growth
- Craniosynostosis
- Rickets
- Delayed motor development and gait abnormalities
- Short stature
- Deformity of weight-bearing limbs
- Tooth abscesses
- Osteomalacia
- Bone and joint pain
- Muscle pain and weakness
- Chiari malformation
- Diminished quality of life including psychosocial impact










As a primary care physician, what should you know about X-linked hypophosphataemia (XLH)?

- XLH is a rare X-linked dominant genetic disorder characterised by renal phosphate wasting.¹ It is the most frequent cause of inherited hypophosphatemia and the most common genetic cause of rickets.¹
- XLH is caused by mutations of Phosphate regulating Endopeptidase X-linked (PHEX) gene (located at Xp22.1).¹ This results in excess Fibroblast Growth Factor 23 (FGF23) leading to renal phosphate wasting and suppressed circulating 1,25(OH)₂D, reducing intestinal phosphate reabsorption.²
- The resulting chronic hypophosphataemia leads to reduced bone mineralisation and rickets/osteomalacia.²

Suspect XLH in PEDIATRIC patients with any of the following signs and symptoms:

“Essential” features for a presumptive diagnosis of XLH in children¹

- | | |
|---|--|
|  <input type="checkbox"/> Decreased growth velocity |  <input type="checkbox"/> Short stature ^{a,b} |
|  <input type="checkbox"/> Progressive lower limb deformities ^b |  <input type="checkbox"/> Persistently elevated ALP levels |
|  <input type="checkbox"/> Renal phosphate wasting ^e – exclude other renal reasons for phosphaturia |  <input type="checkbox"/> Serum phosphate levels below the age-related reference range ^d |
|  <input type="checkbox"/> Radiographic and/or clinical evidence of active rickets that does not heal with ≥ 3 months of calcium and vitamin D treatment ^c | |

a Disproportionate short stature in severe cases (impaired limb growth with preserved trunk growth)









b Primarily in children who have started to walk ($>1-1.5$ years of age)

c Radiographic and/or clinical rickets that does not heal even after 3 months of vitamin D and calcium supplementation - for APAC regions with moderate-to-high prevalence of nutritional rickets

d If clinical suspicion exists and serum phosphate levels are normal, 'fasting' serum phosphate test should be conducted

e Assessed by calculating renal tubular reabsorption of phosphate in the fasting state [TmP/GFR and %TRP] based on urinary and serum phosphate and creatinine levels). The normal TmP/GFR (mmol/L) for children (both sexes) are as follows: at birth (1.43-3.43), 3 months (1.48-3.30), 6 months (1.15-2.60), age 2-15 years (1.15-2.44)³

Additional criteria to support or further confirm the diagnosis of XLH in children¹

- | | |
|--|---|
|  <input type="checkbox"/> Abnormal (waddling) gait |  <input type="checkbox"/> Bone pain |
|  <input type="checkbox"/> Rachitic rosary, Harrison's groove |  <input type="checkbox"/> Recurrent dental abscess |
|  <input type="checkbox"/> Abnormal head shape with frontal bossing |  <input type="checkbox"/> Craniosynostosis, Chiari type 1 malformation |
|  <input type="checkbox"/> Normal serum calcium, normal or mildly elevated PTH, normal 25-hydroxy vitamin D, low or inappropriately normal 1,25-dihydroxy vitamin D, elevated or inappropriately normal FGF23 | |
|  <input type="checkbox"/> Positive family history of XLH and/or detection of pathogenic PHEX gene mutations | |

Abbreviations: ALP, Alkaline phosphatase; APAC, Asia Pacific; TmP/GFR, The ratio of the maximum rate of tubular phosphate reabsorption (TmP) to the glomerular filtration rate (GFR); TRP, Tubular Reabsorption of Phosphate; PTH, Parathyroid hormone



- If you suspect XLH in a pediatric patient based on the above criteria, promptly refer the patient to a specialist.
- Prompt referral, diagnosis and early treatment of XLH is associated with superior clinical outcomes⁴

References: 1. Munns CF, *et al.* JBMR Plus. 2023 May 1;7(6):e10744. 2. Carpenter TO, *et al.* J Bone Miner Res. 2011;26(7):1381-1388. 3. Payne RB. Ann Clin Biochem. 1998;35:201-6. 4. Haffner D, *et al.* Nat Rev Nephrol. 2019;15:435-55.